Alexandre Curie
Research Subjects
Alexandre Curie has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Didier Alcaix
Rheumatology department, Le Havre Monod Hospital, 29, avenue Pierre-Mendes France, 76290 Montivilliers, France
3 shared publications - Pauline Brevet
Univ Rouen Normandie, Inserm, PANTHER UMR 1234, CHU Rouen, Department of Rheumatology & CIC-CRB 1404, 76000 Rouen, France
3 shared publications - C. Princivil
Rheumatology department, Le Havre Monod Hospital, 29, avenue Pierre-Mendes France, 76290 Montivilliers, France
2 shared publications - C. Zarnitsky
Rheumatology department, Le Havre Monod Hospital, 29, avenue Pierre-Mendes France, 76290 Montivilliers, France
2 shared publications - Arnaud François
Pathology Department, Rouen University Hospital, Rouen, France
1 shared publication - Baptiste Dilly
Nephrology department, Rouen University Hospital, 147 avenue du Maréchal Juin 76230 Bois Guillaume, Rouen, France
1 shared publication
Latest Publications
- 1 September 2021
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 42 (9) , 650-653
Vascularites à ANCA précédées d’une atteinte articulaire isolée. À propos de deux cas et revue de la littérature
- 1 September 2021
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 42 (9) , 650-653
Vascularites à ANCA précédées d’une atteinte articulaire isolée. À propos de deux cas et revue de la littérature
- 2 June 2020
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 27 (8S) , S403-S404
Auto-Inflammatory Syndromes Revealing Hematological Disorders and Anakinra Efficacy in 2 Cases
An abstract is unavailable. This article is available as a PDF only.
- 2 June 2020
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 27 (8S) , S403-S404
Auto-Inflammatory Syndromes Revealing Hematological Disorders and Anakinra Efficacy in 2 Cases
An abstract is unavailable. This article is available as a PDF only.
- 1 May 2020
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 41 (5) , 343-345
Effet indésirable rare d’un anti-IL-1RA
- 1 May 2020
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 41 (5) , 343-345
Effet indésirable rare d’un anti-IL-1RA
- Open Access
- 11 October 2019
- Published by Springer Nature in BMC Nephrology
- Vol. 20 (1) , 1-5
Ipilimumab-induced renal granulomatous arteritis: a case report
Background: Immune Checkpoint Inhibitors (ICPIs) are promising new drugs in treatment of advanced tumours targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD1) or its ligand (PDL-1). Ipilimumab is a monoclonal antibody targeting the CTLA-4 receptor used in treatment of metastatic melanoma. By increasing activity of the immune system, ICPIs lead to immune-related adverse events, such as dermatitis, colitis or hepatitis. ICPIs-related kidney adverse events are rare and acute tubulointerstitial nephritis with or without granuloma have mainly been reported. Case presentation: We report a case of acute kidney injury in a patient with melanoma treated by ipilimumab. Kidney biopsy revealed acute interlobular and juxtaglomerular granulomatous arteritis, which has not yet been reported in patients treated by ICPIs. Kidney function partially recovered after ipilimumab discontinuation and oral prednisone. Unfortunately, the patient died a few months later from progression of his melanoma. Conclusion: This case highlights a new mechanism of acute kidney injury related to ICPIs and supports the interest of kidney biopsy in case of ICPIs related acute renal failure.
- 11 October 2019
- Published by Springer Nature in BMC Nephrology
- Vol. 20 (1) , 1-5
Open AccessIpilimumab-induced renal granulomatous arteritis: a case report
Background: Immune Checkpoint Inhibitors (ICPIs) are promising new drugs in treatment of advanced tumours targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD1) or its ligand (PDL-1). Ipilimumab is a monoclonal antibody targeting the CTLA-4 receptor used in treatment of metastatic melanoma. By increasing activity of the immune system, ICPIs lead to immune-related adverse events, such as dermatitis, colitis or hepatitis. ICPIs-related kidney adverse events are rare and acute tubulointerstitial nephritis with or without granuloma have mainly been reported. Case presentation: We report a case of acute kidney injury in a patient with melanoma treated by ipilimumab. Kidney biopsy revealed acute interlobular and juxtaglomerular granulomatous arteritis, which has not yet been reported in patients treated by ICPIs. Kidney function partially recovered after ipilimumab discontinuation and oral prednisone. Unfortunately, the patient died a few months later from progression of his melanoma. Conclusion: This case highlights a new mechanism of acute kidney injury related to ICPIs and supports the interest of kidney biopsy in case of ICPIs related acute renal failure.